KYMR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

14.63M

+97.82%

-0.785

-11.82%

10.62M

-51.96%

-0.970

+18.24%

10.66M

-7.15%

-1.020

+7.41%

Estimates Revision

The market is revising Downward the revenue expectations for Kymera Therapeutics, Inc. (KYMR) for FY2025, with the revenue forecasts being adjusted by -33.53% over the past three months. During the same period, the stock price has changed by 36.24%.

Revenue Estimates for FY2025

Revise Downward

-33.53%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.51%

In Past 3 Month

Stock Price

Go Up

+36.24%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 73.22 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

20 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

53.00

Averages

73.22

High

90.00

Current: 0.000

Low

53.00

Averages

73.22

High

90.00

Wolfe Research

Outperform -> Peer Perform

downgrade

2026-01-06

New

Reason

Wolfe Research

Price Target

2026-01-06

New

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research downgraded Kymera Therapeutics to Peer Perform from Outperform.

Wolfe Research

Outperform

Peer Perform

downgrade

$92

2026-01-06

New

Reason

Wolfe Research

Price Target

$92

2026-01-06

New

downgrade

Outperform

Peer Perform

Reason

As previously reported, Wolfe Research downgraded Kymera Therapeutics to Peer Perform from Outperform and removed the firm's prior $92 price target. With December follow-through having run its course, the firm believes the stock becomes "a poor investment in 2026" without catalysts and with strong valuation concern from buyside, the analyst tells investors. Kymera is "not a good M&A target" and the "degrader greater than inhibitor" thesis may not play out yet, adds the analyst, who views the stock as still a good investment for long-horizon investors.

B. Riley

Buy

maintain

$80 -> $117

2025-12-22

Reason

B. Riley

Price Target

$80 -> $117

2025-12-22

maintain

Buy

Reason

B. Riley raised the firm's price target on Kymera Therapeutics to $117 from $80 and keeps a Buy rating on the shares. The firm says KT-621 demonstrated strong Phase 1b results in moderate to severe atopic dermatitis. The efficacy was observed even in subjects with minimal prior dupilumab exposure and showed no plateauing at 28 days, the analyst tells investors in a research note.

RBC Capital

Outperform

maintain

$70 -> $103

2025-12-16

Reason

RBC Capital

Price Target

$70 -> $103

2025-12-16

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Kymera Therapeutics to $103 from $70 and keeps an Outperform rating on the shares. The firm has had the chance to further digest Kymera's recent Phase 1b atopic dermatitis data and considering its potential implications, RBC believes there remains additional upside potential for shares even after the data uptick,the analyst tells investors in a research note. Kymera is increasingly well-positioned to be a leader across a wide range of high-opportunity I&I - Immunology and Inflammation - indications with an emerging modality offering a more convenient alternative, the firm added.

Stephens

Loganathan

Overweight

maintain

$65 -> $110

2025-12-11

Reason

Stephens

Loganathan

Price Target

$65 -> $110

2025-12-11

maintain

Overweight

Reason

Stephens analyst Sudan Loganathan raised the firm's price target on Kymera Therapeutics to $110 from $65 and keeps an Overweight rating on the shares after the company reported positive Phase 1b BroADen data in moderate-to-severe atopic dermatitis. The totality of evidence points to a "compelling" efficacy and safety profile that supports durability in subsequent AD and asthma trials, the analyst tells investors.

Mizuho

Outperform

maintain

$81 -> $120

2025-12-11

Reason

Mizuho

Price Target

$81 -> $120

2025-12-11

maintain

Outperform

Reason

Mizuho raised the firm's price target on Kymera Therapeutics to $120 from $81 and keeps an Outperform rating on the shares. The firm sees the company's KT-621 in atopic dermatitis data as "meaningfully de-risking" the program.

Valuation Metrics

The current forward P/E ratio for Kymera Therapeutics Inc (KYMR.O) is -19.50, compared to its 5-year average forward P/E of -15.40. For a more detailed relative valuation and DCF analysis to assess Kymera Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.40

Current PE

-19.50

Overvalued PE

-4.97

Undervalued PE

-25.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.22

Current EV/EBITDA

-12.06

Overvalued EV/EBITDA

-0.68

Undervalued EV/EBITDA

-25.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

36.80

Current PS

124.96

Overvalued PS

58.97

Undervalued PS

14.62

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 169.26% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 169.26% over the last month.

Sold

Bought

KYMR News & Events

Events Timeline

No data

News

5.0

2025-12-14Barron's

Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.

4.5

2025-12-12Barron's

S&P 500 Futures Decline in Pre-Market Session; Fermi and Broadcom Underperform

9.0

2025-12-11Globenewswire

Kymera Receives FDA Fast Track Designation for KT-621, Aiming to Transform Atopic Dermatitis Treatment

People Also Watch

Frequently Asked Questions

What is Kymera Therapeutics Inc (KYMR) stock price today?

The current price of KYMR is 76.69 USD — it has increased 4.4 % in the last trading day.

What is Kymera Therapeutics Inc (KYMR)'s business?

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

What is the price predicton of KYMR Stock?

What is Kymera Therapeutics Inc (KYMR)'s revenue for the last quarter?

Kymera Therapeutics Inc revenue for the last quarter amounts to 2.76M USD, decreased -26.12 % YoY.

What is Kymera Therapeutics Inc (KYMR)'s earnings per share (EPS) for the last quarter?

Kymera Therapeutics Inc. EPS for the last quarter amounts to -0.94 USD, increased 14.63 % YoY.

What changes have occurred in the market's expectations for Kymera Therapeutics Inc (KYMR)'s fundamentals?

How many employees does Kymera Therapeutics Inc (KYMR). have?

Kymera Therapeutics Inc (KYMR) has 188 emplpoyees as of January 08 2026.

What is Kymera Therapeutics Inc (KYMR) market cap?

Today KYMR has the market capitalization of 6.05B USD.